JPWO2016019165A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2016019165A5 JPWO2016019165A5 JP2017505180A JP2017505180A JPWO2016019165A5 JP WO2016019165 A5 JPWO2016019165 A5 JP WO2016019165A5 JP 2017505180 A JP2017505180 A JP 2017505180A JP 2017505180 A JP2017505180 A JP 2017505180A JP WO2016019165 A5 JPWO2016019165 A5 JP WO2016019165A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- injection
- composition
- months
- injections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 14
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 14
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 14
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- 229960000485 methotrexate Drugs 0.000 claims description 9
- 238000002271 resection Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 14
- 206010038848 Retinal detachment Diseases 0.000 claims 4
- 230000004264 retinal detachment Effects 0.000 claims 3
- 208000002367 Retinal Perforations Diseases 0.000 claims 2
- 206010038897 Retinal tear Diseases 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030778P | 2014-07-30 | 2014-07-30 | |
| US62/030,778 | 2014-07-30 | ||
| PCT/US2015/042951 WO2016019165A1 (en) | 2014-07-30 | 2015-07-30 | Methotrexate for proliferative vitreoretinopathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202357A Division JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017523974A JP2017523974A (ja) | 2017-08-24 |
| JP2017523974A5 JP2017523974A5 (enExample) | 2018-09-06 |
| JPWO2016019165A5 true JPWO2016019165A5 (enExample) | 2022-04-27 |
| JP7097181B2 JP7097181B2 (ja) | 2022-07-07 |
Family
ID=55218325
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505180A Active JP7097181B2 (ja) | 2014-07-30 | 2015-07-30 | 増殖性硝子体網膜症用メトトレキサート |
| JP2020202357A Pending JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
| JP2023114963A Pending JP2023145527A (ja) | 2014-07-30 | 2023-07-13 | 増殖性硝子体網膜症用メトトレキサート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202357A Pending JP2021059554A (ja) | 2014-07-30 | 2020-12-07 | 増殖性硝子体網膜症用メトトレキサート |
| JP2023114963A Pending JP2023145527A (ja) | 2014-07-30 | 2023-07-13 | 増殖性硝子体網膜症用メトトレキサート |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10098884B2 (enExample) |
| EP (3) | EP3791883B1 (enExample) |
| JP (3) | JP7097181B2 (enExample) |
| CA (2) | CA3200870A1 (enExample) |
| ES (2) | ES2835499T3 (enExample) |
| WO (1) | WO2016019165A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3200870A1 (en) * | 2014-07-30 | 2016-02-04 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| WO2018027044A1 (en) * | 2016-08-05 | 2018-02-08 | Schepens Eye Research Institute | Idelalisib for treating proliferative vitreoretinopathy and abnormal intraocular neovascularization |
| EP3710008A4 (en) | 2017-11-14 | 2021-08-25 | The Schepens Eye Research Institute, Inc. | RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION |
| JP7682512B2 (ja) * | 2019-09-13 | 2025-05-26 | アルデイラ セラピューティクス， インコーポレイテッド | メトトレキサートの眼科用製剤 |
| CN115804665A (zh) * | 2022-12-13 | 2023-03-17 | 南昌大学附属眼科医院 | 一种tpvr动物模型的建立方法 |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032734A1 (en) | 2000-07-26 | 2002-03-14 | Rhoads Geoffrey B. | Collateral data combined with user characteristics to select web site |
| AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| TW200536861A (en) * | 2004-04-02 | 2005-11-16 | Denki Kagaku Kogyo Kk | Hyaluronic acid/methotrexate compound |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| ATE439123T1 (de) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | Verwendung von emulsionen zur intra- und periocularen injection |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| EP3173072A1 (en) | 2004-10-01 | 2017-05-31 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US20110200662A1 (en) * | 2008-10-22 | 2011-08-18 | Arnold Glazier | Method For The Treatment Of Proliferative Disorders Of The Eye |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| US20140105956A1 (en) * | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| EA034963B1 (ru) * | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Способ лечения расстройства заднего сегмента глаза |
| CA3200870A1 (en) * | 2014-07-30 | 2016-02-04 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
-
2015
- 2015-07-30 CA CA3200870A patent/CA3200870A1/en active Pending
- 2015-07-30 EP EP20191599.8A patent/EP3791883B1/en active Active
- 2015-07-30 EP EP15827946.3A patent/EP3174540B9/en active Active
- 2015-07-30 JP JP2017505180A patent/JP7097181B2/ja active Active
- 2015-07-30 CA CA2991921A patent/CA2991921C/en active Active
- 2015-07-30 US US15/500,351 patent/US10098884B2/en active Active
- 2015-07-30 EP EP23205570.7A patent/EP4311575A3/en not_active Withdrawn
- 2015-07-30 WO PCT/US2015/042951 patent/WO2016019165A1/en not_active Ceased
- 2015-07-30 ES ES15827946T patent/ES2835499T3/es active Active
- 2015-07-30 ES ES20191599T patent/ES2969374T3/es active Active
-
2017
- 2017-09-08 US US15/699,559 patent/US10272089B2/en active Active
-
2019
- 2019-04-29 US US16/397,562 patent/US10828306B2/en active Active
-
2020
- 2020-10-30 US US17/085,907 patent/US20210283135A1/en not_active Abandoned
- 2020-12-07 JP JP2020202357A patent/JP2021059554A/ja active Pending
-
2023
- 2023-07-13 JP JP2023114963A patent/JP2023145527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021059554A5 (enExample) | ||
| Beckers et al. | Safety and effectiveness of the PRESERFLO® MicroShunt in primary open-angle glaucoma: results from a 2-year multicenter study | |
| Kreiger et al. | Management of giant retinal tears without scleral buckling: use of radical dissection of the vitreous base and perfluoro-octane and intraocular tamponade | |
| Fechtner et al. | Complications of glaucoma surgery: ocular decompression retinopathy | |
| Agrawal et al. | Cataract surgery in uveitis | |
| Schneider et al. | Ocular perforation from a retrobulbar injection | |
| Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
| Simone et al. | Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery | |
| Duffin et al. | Inhibitors of surgically induced miosis | |
| Stewart et al. | Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery | |
| Topilow et al. | The treatment of advanced retinopathy of prematurity by cryotherapy and scleral buckling surgery | |
| JP7097181B2 (ja) | 増殖性硝子体網膜症用メトトレキサート | |
| McDonald et al. | Vitreous surgery for retinal detachment associated with choroidal coloboma | |
| MXPA05000773A (es) | Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad. | |
| Vanathi et al. | Iatrogenic crystalline lens injury in pediatric eyes following intravitreal injection for retinopathy of prematurity | |
| JPWO2016019165A5 (enExample) | ||
| Diolaiuti et al. | Combined pars plana vitrectomy and phacoemulsification with intraocular lens implantation in severe proliferative diabetic retinopathy | |
| Crawford et al. | Endocapsular artificial iris implantation for iris defects: reducing symptoms, restoring visual function and improving cosmesis | |
| Graff et al. | Conjunctiva and Tenon's capsule handling in the Port Delivery System with ranibizumab implant insertion procedure: surgical pearls | |
| RU2712392C1 (ru) | Способ микроинвазивного комбинированного лазерхирургического лечения локальной регматогенной отслойки сетчатки вследствие клапанного разрыва при наличии частичного гемофтальма | |
| Yang et al. | Corneal melting with intraocular lenses | |
| Harris et al. | Implantation of a sustained-release ganciclovir implant | |
| Rodriguez-Garcia et al. | Cataract surgery in patients with uveitis: preoperative and surgical considerations | |
| Forster | Corneoscleral block excision of postoperative anterior chamber cysts | |
| Talley et al. | Use of the 193 nm excimer laser for photorefractive keratectomy in low to moderate myopia |